Malaria Vaccine Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Vaccine Type (Pre-Erythrocytic, Erythrocytic, Multi-antigen, Others), By Route of Administration (Intramuscular, Subcutaneous, Intradermal, Others), Region and Competition
Published Date: November - 2024 | Publisher: MIR | No of Pages: 320 | Industry: Healthcare | Format: Report available in PDF / Excel Format
View Details Buy Now 2890 Download Sample Ask for Discount Request CustomizationMalaria Vaccine Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Vaccine Type (Pre-Erythrocytic, Erythrocytic, Multi-antigen, Others), By Route of Administration (Intramuscular, Subcutaneous, Intradermal, Others), Region and Competition
Advancements in biotechnology have significantly accelerated the development of malaria vaccines. In recent years, there has been a greater understanding of the molecular and cellular mechanisms involved in malaria infection, which has led to the identification of potential vaccine candidates. Additionally, advances in vaccine development technologies, such as DNA vaccines and viral vector-based vaccines, have allowed for the creation of more effective and safer malaria vaccines, thereby opening new prospects for the growth of global malaria vaccine market in the next few years.
The growth of the malaria vaccine market faces several challenges, including scientific complexities due to the complex nature of the malaria parasite and its ability to mutate rapidly, financial constraints in terms of research and development costs, regulatory hurdles for approval and distribution, limited infrastructure in some regions for effective vaccine distribution, and the growing trend of vaccine hesitancy and political instability in malaria-endemic areas. Developing a vaccine requires approval from regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). This process can be lengthy and expensive, and the requirements for approval can be stringent, making it difficult for smaller companies to navigate the process.
Increasing Prevalence of Malaria
Nearly half of the world's population was predicted to be in danger of malaria in 2021 by WHO. 619 000 deaths from malaria were anticipated in 2021. A disproportionately large amount of the worldwide malaria burden is placed on the WHO African Region. 95% of malaria cases and 96% of malaria deaths occurred in the Region in 2021. In the region, 80% of all malaria deaths were in children under the age of five.
Increasing Research & Development
Increasing Investments
Increasing investment in developing and improvising healthcare infrastructure is another important driver of the growth of the global malaria vaccine market. The development of effective malaria vaccines is only one part of the solution to combating this disease. Equally important is the establishment of a strong healthcare infrastructure that can effectively deliver vaccines to those who need them. In many low- and middle-income countries where malaria is most prevalent, healthcare infrastructure is often inadequate or nonexistent, making it difficult to effectively deliver vaccines and other essential healthcare services. Increasing investment in healthcare infrastructure can help to address this problem by improving the availability and accessibility of healthcare services, including vaccines. This includes investment in healthcare facilities, medical equipment, healthcare personnel, and healthcare logistics. For instance, investment in the construction of new healthcare facilities, such as clinics and hospitals, can help to expand access to healthcare services in underserved areas. Investment in medical equipment, such as refrigerators and freezers, can help to ensure that vaccines are stored properly and remain effective. Increased investment in healthcare infrastructure has been supported by both government and private sector funding. Increasing investment in healthcare infrastructure is driving the growth of the global malaria vaccine market by improving the availability and accessibility of healthcare services, including vaccines.
Recent Developments
The malaria vaccine, known as R21/Matrix-M, which is manufactured by the Serum Institute of India, has received clearance from the Ghanaian government to be used in the country. This marks a significant step forward in the fight against malaria, which is a major public health problem in Ghana and other sub-Saharan African countries.
Mosquirix is a vaccine that is designed to provide protection against Plasmodium falciparum, the deadliest species of malaria parasite. The vaccine was developed by GlaxoSmithKline (GSK) in partnership with the PATH Malaria Vaccine Initiative, and it has been approved for use by the European Medicines Agency (EMA).
CVac is a whole-parasite malaria vaccine that uses genetically modified parasites to stimulate an immune response. In 2021, Novartis announced that it had completed a Phase 1 clinical trial of the CVac vaccine, which showed that the vaccine was safe and well-tolerated in healthy volunteers. The company plans to move forward with Phase 2 clinical trials to evaluate the efficacy of the vaccine.
In 2021, Serum Institute of India announced that it had partnered with the University of Oxford to develop a new mRNA-based malaria vaccine. The vaccine will use the same technology that was used to develop the Pfizer-BioNTech and Moderna COVID-19 vaccines. The mRNA vaccine has the potential to provide a more effective immune response compared to traditional vaccines.
Download Free Sample Report
Market Segmentation
Global Malaria Vaccine Market can be segmented by vaccine type, by route of administration, and by region. Based on vaccine type, global malaria vaccine market can be divided into Pre-Erythrocytic, Erythrocytic, Multi-antigen, and Others. Based on route of administration, the global malaria vaccine market is divided into Intramuscular, Subcutaneous, Intradermal, and Others. Regionally, the Malaria Vaccine Market can be categorized into North America, Europe, Asia Pacific, South America, and Middle East & Africa.
Market Players
GlaxoSmithKline, Plc., Novartis AG, Takeda Pharmaceutical Company, Sanaria Inc., Merck & Co., Johnson & Johnson, Pfizer Inc., Serum Institute of India Private Limited, Bharat Biotech International Limited, Moderna Inc are some of the leading players operating in the Global Malaria Vaccine Market.
| Attribute | Details |
| Base Year | 2022 |
| Historic Data | 2018 – 2021 |
| Estimated Year | 2023 |
| Forecast Period | 2024 – 2028 |
| Quantitative Units | Revenue in USD Million, and CAGR for 2018-2022 and 2023-2028 |
| Report coverage | Revenue forecast, volume forecast, company share, competitive landscape, growth factors, and trends |
| Segments covered | By Vaccine Type By Route of Administration By End User |
| Regional Scope | North America, Europe, Asia Pacific, South America, Middle East & Africa |
| Country Scope | United States, Canada, Mexico, United Kingdom, Germany, France, Italy, Spain, India, Japan, South Korea, Australia, Vietnam, Indonesia, Myanmar, Brazil, Colombia, South Africa, Saudi Arabia, UAE, Egypt, Turkey, Nigeria |
| Key companies profiled | GlaxoSmithKline, Plc., Novartis AG, Takeda Pharmaceutical Company, Sanaria Inc., Merck & Co., Johnson & Johnson, Pfizer Inc., Serum Institute of India Private Limited, Bharat Biotech International Limited, Moderna Inc |
| Customization scope | 10% free report customization with purchase. Addition or alteration to country, regional & segment scope. |
| Pricing and purchase options | Avail customized purchase options to meet your exact research needs. Explore purchase options |
| Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
FAQ'S
For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:
Within 24 to 48 hrs.
You can contact Sales team (sales@marketinsightsresearch.com) and they will direct you on email
You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.
Discounts are available.
Hard Copy